Exhibit (a)(7)

Cowen & Company 27th Annual Healthcare Conference March 14, 2007 Matthew Emmens, CEO Shire plc

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical facts are forward -looking statements. Such forward -looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to: risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (guanfacine extended release) (ADHD) and SPD465 (extended release of mixed amphetamine salts) (ADHD); Shire's ability to secure new products for commercialization and/or development; Shire's planned acquisition of New River Pharmaceuticals announced February 20, 2007; and other risks and uncertainties detailed from time to time in Shire's and its predecessor registrant Shire Pharmaceuticals Group plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006. Goldman Sachs International, Morgan Stanley and Deutsche Bank, which are authorized and regulated in the United Kingdom by the Financial Services Authority, are acting exclusively for Shire in relation to the acquisition and no one else and will not be responsible to anyone other than Shire for providing the protections afforded to its customers or for providing advice in relation to the acquisition or in relation to any transaction, arrangement or other matter referred to in this announcement. 2

Acquisition Rationale Shire agrees to buy New River for $2.6 billion to gain control of VYVANSE -future flagship ADHD product

Why New River? Logical strategic move Innovative drug - the next generation of ADHD treatment Attractiveness of the ADHD market 4

Transaction Financing All cash transaction valued at $2.6bn to be funded by cash: Committed new bank facilities of $2.3bn Existing $700 million facilities were cancelled Placing of new ordinary shares raised approximately $900 million Executed by way of accelerated book built private placement to certain institutional investors Represents approximately 8.4% of Shire's issued ordinary share capital prior to the Placing* *Based on closing price of Shire shares on LSE on February 19, 2007 of (pound)10.75 5

New River Acquisition Terms All cash transaction $64 per share (approximately $2.6 billion total) 10% premium to New River's closing price on 16 February 2007 14% average price over the last 4 weeks prior to closing date RJ Kirk, New River's CEO, who beneficially owns 50.2% of the total outstanding shares of New River common stock has agreed pursuant to a tender and support agreement with Shire that he will tender his shares in the tender offer Subject to shareholder and regulatory approvals - anticipated to close by the end of Q2 2007 Retain our financial flexibility to make further acquisitions 6

Rationale Logical strategic move Transition from ADDERALL XR Gain full economic benefit of the drug Significantly enhances Shire's EPS growth from late 2009 Fully control development and commercialization strategy Further studies in ADHD, additional product indications Adds to Shire's product pipeline and broadens technology platform 7

Rationale Unique drug - next generation of ADHD treatment VYVANSE innovative and future flagship product for ADHD Favorable therapeutic profile; long acting, lower abuse potential FDA approval received on February 23 Strong IP until 2024 Attractiveness of the ADHD market 6% potential annual US prescription growth Adult market opportunities Europe - plan to file VYVANSE in 2009 8

VYVANSE provides duration of effect throughout the day Change in LS Mean Score at Endpoint From Baseline on Conners' Parent Rating Scale (CPRS) Across the Day Median daily dosing time was between 7:30 AM and 8 AM. The CPRS was used to assess the duration of therapeutic response in 285 patients by separately analyzing the assessments performed per protocol in the morning (~10 AM), afternoon (~2 PM), and evening (~6 PM). *P less than .0001 vs placebo. Data on file. Shire US Inc. 9

Incidence of Vyvanse Most Common Adverse Events Over Time 1st Occurrence or Recurrence Decreased appetite Abdominal pain Insomnia Irritability Data on file, Shire US Inc. Difference between 218 vs 178 includes patients that violated the protocol or did not follow up for Check up. 10

Study Shows Global ADHD Growth "ADHD could become the leading childhood disorder treated with medications across the globe." - Richard Scheffler, Reuters, 3/6/07 "The usage of ADHD medications increased 274 percent during the study period. " - Medical journal Health Affairs "Cross-cultural research has shown that ADHD exists in all cultures, with increased access to public education a factor in its detection. " - Psychologist Stephen Hinshaw of UC Berkeley *Study period 1993 - 2003 11

US ADHD Prevalence and Treatment Pediatric Patients (4-17)* Adult Patients* Prevalence Treated * 2004 NHIS (National Health Interview Survey, given by CDC); Kessler et al, 2005 12

Growth in European ADHD market Circa $200 million market growing at CAGR > 70% and likely to more than double by 2010 EUROPE FRANCE GERMANY SWITZERLAND UNITED KINGDOM IRELAND SPAIN BENELUX SWEDEN Source: IMS 13

Scientific efforts in ADHD advancing dramatically across Europe Diagnosis of ADHD evolving in Europe Increasing adoption of US diagnostic criteria (DSM-IV*) ADHD treatment guidelines being developed and communicated Pan - European Guidelines NICE - 2000; 2006; 2008/09 (planned) British Association of Psychopharmacology - 2006 (ADHD in Adults) Increased clinical research in ADHD in Europe Germany, UK, Netherlands leading the way * DSM-IV = Diagnostic and Statistical Manual of Mental Health Disorders 14

The Next Generation, Prodrug Stimulant for ADHD 15

2006 Year End Review

2006 Financial Highlights Product sales up 16% to $1,536 million Total revenues up 12% to $1,797 million Cash and cash equivalents up $470 million Dividends up 15% EPS (diluted) GAAP $ 1.64 Non GAAP(excluding FAS 123R) $ 1.87 Cash EPS(excluding FAS 123R and amort.) $ 2.11 17

2006/2007 Highlights - Executing on Strategy Expansion of the business through significant advancement of our late stage pipeline ADHD VYVANSE - Approval received - launch planned Q2 2007 DAYTRANA - transdermal patch, successful US launch in progress SPD465 - long-acting stimulant for adults - May 21, 2007 SPD503 - non-stimulant for pediatric - June 24, 2007 GI LIALDA / MEZAVANT - launch planned Q2 2007 2.4g/d to 4.8 g/d (2 to 4 tablets) taken once daily for induction of remission and 2.4g/d (2 tablets) taken once daily for maintenance of remission 18

2006/2007 Highlights - Executing on Strategy Renal FOSRENOL - now launched in Germany and France; to be launched in UK, Spain and Italy in 2007 US co-promote agreement with Abbott Laboratories - effective as of February 2007 DYNEPO - Q2 07 European launch planned Human Genetic Therapies ELAPRASE - US and European launches in progress 261 patients globally on therapy at the end February 2007 400 additional patients identified globally REPLAGAL - Approval received in Japan - launch planned for Q2 2007 19

Early stage pipeline to develop future product candidates GA-GCB: phase 3 clinical program initiated in Gaucher disease Three enzyme replacement projects advanced to pre-clinical development Sanfililppo (Mucopolysaccharidosis IIIA) Metachromatic Leukodystrophy Hunter syndrome CNS SPD500 (tissue protective cytokines pre-clinical): in-licensed from Warren Pharmaceuticals for renal and genetic disease areas SPD493 (Valrocemide Phase 1): in-licensed from Yissum Research and Development Company for CNS disorders New SPD491: once-a-day, non-opiate, transdermal analgesic with the goal of non-scheduled labelling to treat moderate to severe pain New SPD535: pre-clinical evaluation of a novel compound for the treatment of platelet reduction 20

Outlook - 2007 t 0 0 Shire's EPS , Non GAAP measure for 2007 will be Cash being GAAP EPS excluding significant milestone payments, amortization (up approx 20% over 2006) and FAS123R (approx $45m). The following guidance excludes these costs and the impact of the New River acquisition. 2007 revenue growth expected to be around 20% (assuming prescription growth in the ADHD market of 4-6%). Earnings for 2007 will continue to be impacted by costs associated with the ongoing development and launch of new products. Up to 6 new products to be launched during 2007 and H1 2008 in addition to the continued growth of DAYTRANA, ELAPRASE & FOSRENOL in the US and ELAPRASE & FOSRENOL in Europe; Launches will require additional advertising and promotional spend and in some cases additional sales representatives. Consequently, SG&A expected to rise to between $930-960m for 2007; Phase 3(b) and Phase 4 studies to support new product launches, the continuation of phase 3 trials on GA-GCB, the development of the Women's Health franchise, pre-clinical development of 3 HGT projects and 2 further pre-clinical projects expected to result in R&D spend in the range of $360-380m. Depreciation is expected to increase by approximately 20% compared to 2006; and Estimated tax rate - approximately 26% (down 1%). 21

Concluding Remarks

Concluding Remarks Shire to gain control of VYVANSE, future flagship product for ADHD Logical strategic move Innovative drug - next generation of ADHD treatment Attractiveness of the ADHD market Retain our financial flexibility to make further acquisitions 23

2006 Results - Concluding Remarks Excellent results - the business continues to perform strongly Successful launches in 2006 with guidance for robust revenue growth Continuing to demonstrate our ability to execute ADDERALL XR - leading US market share DAYTRANA - strong launch ELAPRASE - approved in US and EU FOSRENOL - strong start in Europe SPD465 - PDUFA May 21, 2007 SPD503 - PDUFA June 24, 2007 Additional product launches by mid-2007 - on track VYVANSE LIALDA / MEZAVANT DYNEPO Early stage pipeline advancing toward clinical development 24

Questions and Answers All

APPENDIX

Total Revenues 2006 2005 $m $m Product Sales 1,535.8 1,327.7 + 16% Royalties 242.9 242.9 Other Revenue 17.8 28.7 Total Revenues 1,796.5 1,599.3 + 12% 27

Major Product Sales 2006 2005 Sales US RX* $m $m Growth Growth ADDERALL XR 863.6 730.8 + 18% + 8% PENTASA 137.8 136.1 + 1% + 2% REPLAGAL 117.7 ** 94.6 + 24% N/A CARBATROL 68.3 72.1 -5% -9% XAGRID*** 53.3 46.8 + 14% N/A FOSRENOL 44.8 53.5 -16% + 34% DAYTRANA 25.1 N/A N/A N/A ELAPRASE 23.6 N/A N/A N/A * Source: IMS Data ** Includes t 0 0 pre-acquisition sales of $53.3m *** worldwide sales excluding US and Canada 28

Royalties 2006 2005 Growth $m $m 3TC 150.9 159.8 -6% ZEFFIX 34.8 30.5 + 14%* Other ** 57.2 52.6 + 9% Total 242.9 242.9 0% * Foreign exchange movements have contributed +1% to reported growth ** Includes REMINYL/RAZADYNE 29

Financial Ratios (on a non-GAAP basis, excluding FAS123R) 2006 2005 COGS : Product sales 13% 13% Gross margin 87% 87% R&D : Revenues 17% 18% SG&A (excl. D&A) : Product sales 52% 48% Operating margin 22% 27% This slide contains non GAAP financial measures. Management believes that the presentation of these non GAAP financial measures provide useful information to investors regarding Shire's performance as the excluded items are not indicative of the ongoing business in 2006 & 2005. 30

Cash flow -2006 Millions of USD Cash generation + 581 Tax / interest + 39 Net fixed asset purchases - 109 Product milestones - 59 R+D payments - 81 Adderall IR Sale + 63 IDB loan repayment + 71 Equity financing - 42 Cash surplus for 2006 (1) : + 463 (1) Cash & cash equivalents up $470m less short term investments down $7m. Net Cash at 31.12.05 694 Cash Surplus 31.12.06 463 Net Cash at 31.12.06 1,157 Provision for amounts due (452) for appraisal rights Restricted cash (30) "Free Cash" at 31/12/06 675 31

Net Income/EPS 2006 2005(1) Net income ($m) - GAAP 278.2 (578.4) - Adjustments 10.7 892.4 - Non GAAP(2) 288.9 314.0 -8% EPS (diluted): - ADS 163.8c (346.8c) Non GAAP EPS (diluted)(2) - ADS 170.1c 187.8c -9% Non GAAP EPS (diluted)(2) - ADS (excluding FAS123R) 187.2c 201.4c -7% (1) Adjusted to reflect retrospective adoption of SFAS 123R and restated for the correction to the value of TKT's IPR&D (2) These are non GAAP financial measures. They exclude items that management believe are not indicative of the ongoing business in 2006 & 2005. 32

2006 Actual v Guidance Actual Guidance Revenue growth 12.3% 12% - 14% R&D - GAAP ($m) 387 Less New River milestone (50) Warren up front (6) Duramed up front (25) FAS123R (5) R&D - Non GAAP ($m) $ 301 $ 310m to $330m SG&A - GAAP ($m) 835 Less: FAS123R (34) SG&A - Non GAAP ($m) $ 801 $ 770m to $800m D&A increase 34% 30% Tax rate 27% 28% 33

2006 Cash EPS 2006 2005 Non GAAP EPS (diluted)(1) - ADS 170.1c 187.8c -9% Non GAAP EPS (diluted)(1) - ADS (excluding FAS123R) 187.2c 201.4c -7% Cash EPS (diluted)(2) - ADS (excluding FAS123R and 211.2c 220.7c -4% amortisation) (1) These are non GAAP financial measures. They exclude items that management believe are not indicative of the ongoing business in 2006 & 2005. (2) This represents cash EPS and will be the measure which management intend to use for guidance in 2007 34

EPS Reconciliation 2006 2006 2005(1) 2005(1) $m cents/ADS $m cents/ADS Net income for diluted EPS (ADS) 278.2 163.8c (578.4) (346.8c) TKT in-process R&D write-off - - 815.0 487.5c Cost of product sales fair value adjustment 47.0 27.7c 41.9 25.2c New River milestone and upfront payments 50.0 29.5c 50.0 30.0c Up-front license payments (Duramed & Warren) 30.5 18.0c - - Reorganisation / integration costs 5.6 3.3c 23.6 13.8c Gain on disposal of drug formulation business - (3.6) (2.1c) Gain on sale of product rights (63.0) (37.1c) - - Taxes on above adjustments (18.8) (11.1c) (31.4) (18.0c) less dilution impact of Non GAAP adj Gain on disposition of discontinued operations (40.6) (24.0c) (3.1) (1.8c) Net income for non GAAP EPS (ADS) 288.9 170.1c 314.0 187.8c FAS 123R effect (net of tax) 31.3 17.1c 25.6 13.6c Net income for non GAAP EPS (ADS) (ExFAS 123R) 320.2 187.2c 339.6 201.4c Amortisation (net of tax) 41.2 24.0c 32.5 19.3c Net income for non GAAP EPS (ADS) (Ex 361.4 211.2c 372.1 220.7c FAS123R and amortisation) (1) Adjusted to reflect retrospective adoption of SFAS 123R and restated for the correction to the value of TKT's IPR&D (2) These are non GAAP financial measures. They exclude items that management believe are not indicative of the ongoing business in 2006 & 2005. 35

Additional Information This presentation is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell New River common stock. The tender offer is being made pursuant to a tender offer statement on Schedule TO (including the offer to purchase, letter of transmittal and other related tender offer materials, which were mailed to New River's shareholders) filed by a subsidiary of Shire with the Securities and Exchange Commission ("SEC") on March 2, 2007. In addition, on March 2, 2007, New River filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer, which was mailed to New River's shareholders. The tender offer statement (and related materials), as it may be amended from time to time, and the solicitation/recommendation statement, as it may be amended from time to time, contain impo rtant information, including the various terms of, and conditions to, the tender offer, that should be read carefully before any decision is made with respect to the tender offer. These materials may be obtained free of charge by contacting the information agent for the tender offer, Innisfree M&A Incorporated, at (888) 750-5834 (toll-free from the U.S. or Canada) or (412) 232-3651 (toll-free from outside the U.S. and Canada) . In addition, all of these materials (and all other materials filed by New River and Shire with the SEC) are available for free at the website maintained by the SEC at www.sec.gov. 36